{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T19:29:34Z","timestamp":1757618974292,"version":"3.44.0"},"reference-count":26,"publisher":"BMJ","issue":"5","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Eur J Hosp Pharm"],"accepted":{"date-parts":[[2019,7,24]]},"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1136\/ejhpharm-2019-001891","type":"journal-article","created":{"date-parts":[[2019,8,12]],"date-time":"2019-08-12T17:15:34Z","timestamp":1565630134000},"page":"280-283","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Improving policies and practices for the extemporaneous compounding of oral liquid dosage forms in Saudi Arabian hospitals"],"prefix":"10.1136","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5114-9230","authenticated-orcid":false,"given":"Imraan","family":"Joosub","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Saudi Arabia Ministry of National Guard, Al-Madina, Madina Province, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zohair","family":"Emara","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Saudi Arabia Ministry of National Guard, Al-Madina, Madina Province, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andy","family":"Gray","sequence":"additional","affiliation":[{"name":"Division of Pharmacology, Discipline of Pharmaceutical Sciences, University of KwaZulu-Natal, Durban, KwaZulu-Natal, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2019,8,12]]},"reference":[{"key":"2025090703240747000_28.5.280.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2008.11.020"},{"key":"2025090703240747000_28.5.280.2","first-page":"398","article-title":"Stability considerations in liquid dosage forms extemporaneously prepared from commercially available products","volume":"9","author":"Glass","year":"2006","journal-title":"J Pharm Pharm Sci"},{"key":"2025090703240747000_28.5.280.3","unstructured":"US-FDA . The special risks of pharmacy compounding, 2012. Available: https:\/\/www.pharmwatch.org\/reports\/compounding_risks.pdf [Accessed 23 Aug 2017]."},{"key":"2025090703240747000_28.5.280.4","unstructured":"Anon . U.S. Pharmacopeia and National Formulary, USP <795> rev. Rockville: United States Pharmacopeial Convention, Incorporated, 2014."},{"key":"2025090703240747000_28.5.280.5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40268-013-0005-9","article-title":"Potential risks of pharmacy compounding","volume":"13","author":"Gudeman","year":"2013","journal-title":"Drugs in R&D"},{"key":"2025090703240747000_28.5.280.6","unstructured":"Saudi Food & Drug Authority . Manufacturing and compounding of medications. Saudi FDA: Kingdom of Saudi Arabia, 2010."},{"key":"2025090703240747000_28.5.280.7","unstructured":"World Health Organization . Technical report series, FIP-WHO technical guidelines: points to consider in the provision by health-care professionals of children-specific preparations that are not available as authorized products. World Health Organization, 2016."},{"key":"2025090703240747000_28.5.280.8","unstructured":"Trissel LA . Trissel's stability of compounded formulations. 5th edn. Washington, DC: American Pharmacists Association, 2012."},{"key":"2025090703240747000_28.5.280.9","doi-asserted-by":"crossref","unstructured":"Jew RK , Soo-Hoo W , Erush SC , et al . Extemporaneous formulations for pediatric, geriatric, and special needs patients. American Society of Health-System Pharmacists, 2016.","DOI":"10.37573\/9781585285259"},{"key":"2025090703240747000_28.5.280.10","unstructured":"Allen LV . The art, science, and technology of pharmaceutical compounding. 4th edn. Washington DC: American Pharmacists Association, 2012 .."},{"key":"2025090703240747000_28.5.280.11","unstructured":"Abdurraheem MA . The art of pharmaceutical compounding. 3rd edn. King Fahd National Library Catalogue-in-Publication Data, 2006."},{"key":"2025090703240747000_28.5.280.12","unstructured":"Shaker NF . Extemporaneous preparations: adult and pediatric guide. 1st edn. Saudi Arabia: Dar al-Shawaf, 2012."},{"key":"2025090703240747000_28.5.280.13","first-page":"186","article-title":"Stability of amiodarone in extemporaneous oral suspensions prepared from commercially available vehicles","volume":"4","author":"Nahata","year":"1999","journal-title":"J Pediatr Pharm Pract"},{"key":"2025090703240747000_28.5.280.14","first-page":"525","article-title":"An overview of United States pharmacopeia chapter 795 and American Society of Health-System Pharmacists guidelines for nonsterile compounding","volume":"13","author":"McElhiney","year":"2009","journal-title":"Int J Pharm Compd"},{"key":"2025090703240747000_28.5.280.15","unstructured":"Bachenheimer BS . Manual for pharmacy technicians. 4th edn. American Society of Health-System Pharmacists, 2010 .."},{"key":"2025090703240747000_28.5.280.16","first-page":"428","article-title":"Stability of levothyroxine, doxycycline, hydrocortisone, and pravastatin in liquid dosage forms stored at two temperatures","volume":"19","author":"Nahata","year":"2015","journal-title":"Int J Pharm Compd"},{"key":"2025090703240747000_28.5.280.17","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1093\/ajhp\/53.10.1157","article-title":"Stability of an extemporaneously compounded levothyroxine sodium oral liquid","volume":"53","author":"Boulton","year":"1996","journal-title":"Am J Health Syst Pharm"},{"key":"2025090703240747000_28.5.280.18","first-page":"60","article-title":"Stability of an extemporaneously formulated levothyroxine sodium syrup compounded from commercial tablets","volume":"1","author":"Alexander","year":"1997","journal-title":"Int J Pharm Compd"},{"key":"2025090703240747000_28.5.280.19","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-1891"},{"key":"2025090703240747000_28.5.280.20","first-page":"1","article-title":"The stability of folic acid suspension","volume":"5","author":"Gunasekaran","year":"2015","journal-title":"Int J Sci Res Publ"},{"key":"2025090703240747000_28.5.280.21","first-page":"332","article-title":"Stabilization of folic acid in liquid dosage form: formulation development, method validation and comparative analysis","volume":"1","author":"Vignesh","year":"2012","journal-title":"Int J Pharm Chem Sci"},{"key":"2025090703240747000_28.5.280.22","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp180085"},{"key":"2025090703240747000_28.5.280.23","doi-asserted-by":"crossref","DOI":"10.1136\/ejhpharm-2018-001727","article-title":"Formulation and compatibility studies are important","volume":"25","author":"Wiffen","year":"2018","journal-title":"Eur J Hosp Pharm"},{"key":"2025090703240747000_28.5.280.24","unstructured":"Nahata MC , Pai VB . Pediatric drug formulations. 5th edn. Harvey Whitney Books, 2004."},{"key":"2025090703240747000_28.5.280.25","doi-asserted-by":"publisher","DOI":"10.1177\/106002809703100707"},{"key":"2025090703240747000_28.5.280.26","first-page":"389","article-title":"Formulation and accelerated stability studies for an extemporaneous suspension of amiodarone hydrochloride","volume":"7","author":"Alexander","year":"2003","journal-title":"Int J Pharm Compd"}],"container-title":["European Journal of Hospital Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ejhpharm-2019-001891","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T10:24:13Z","timestamp":1757240653000},"score":1,"resource":{"primary":{"URL":"https:\/\/ejhp.bmj.com\/lookup\/doi\/10.1136\/ejhpharm-2019-001891"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,12]]},"references-count":26,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2021,8,23]]},"published-print":{"date-parts":[[2021,9]]}},"alternative-id":["10.1136\/ejhpharm-2019-001891"],"URL":"https:\/\/doi.org\/10.1136\/ejhpharm-2019-001891","relation":{},"ISSN":["2047-9956","2047-9964"],"issn-type":[{"type":"print","value":"2047-9956"},{"type":"electronic","value":"2047-9964"}],"subject":[],"published":{"date-parts":[[2019,8,12]]}}}